Premium
In situ photoimmunotherapy for cutaneous granuloma caused by itraconazole‐resistant Candida guilliermondii
Author(s) -
Shi Lei,
Luo Min,
Chen Wei R.,
Hu Chan,
Zhang Guolong,
Zhang Fuhe,
Chen Jia,
Mo Xiaohui,
Cai Qing,
Yang Lianjuan,
Wang Xiuli
Publication year - 2016
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12376
Subject(s) - medicine , itraconazole , actinic keratosis , dermatology , granuloma annulare , granuloma , imiquimod , pathology , antifungal , basal cell
Cutaneous granulomas caused by Candida guilliermondii are difficult to cure. In situ photoimmunotherapy (ISPI) is a novel method composed of local photothermal therapy and immunoadjuvant. In this study, ISPI was used the first time clinically for cutaneous granuloma caused by itraconazole‐resistant C.guilliermondii. A 10‐week cycle of ISPI was composed of (1) 5% imiquimod applied topically every other day and (2) irradiation of lesions with an 808‐nm diode laser at Days 14, 28, 42, and 56. Here we report our first case. A patient was treated with ISPI for four cycles. After the treatment, the lesions were eliminated without recurrence during a 12‐month follow‐up. Our results demonstrate that ISPI can be used as an effective treatment modality for cutaneous fungal granuloma.